Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.23 HKD | +1.95% | 0.00% | -21.23% |
May. 02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
Apr. 10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
Business Summary
Number of employees: 435
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biologics of Oncology
100.0
%
| 194 | 100.0 % | 242 | 100.0 % | +24.60% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 194 | 100.0 % | 242 | 100.0 % | +24.60% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ting Xu
CEO | Chief Executive Officer | 51 | 08-10-31 |
Jing Han
CMP | Compliance Officer | 51 | 21-11-01 |
Jinbo Wang
CTO | Chief Tech/Sci/R&D Officer | 50 | 18-03-18 |
Liang Kong
CTO | Chief Tech/Sci/R&D Officer | 44 | 18-05-31 |
Lu Amy Sun
CTO | Chief Tech/Sci/R&D Officer | 67 | 19-05-31 |
Yang Liu
COO | Chief Operating Officer | 52 | 18-09-30 |
Jin Nan Wang
IRC | Investor Relations Contact | 42 | - |
Shaowei Yang
PRN | Corporate Officer/Principal | 48 | 17-06-12 |
Mike Liu
PRN | Corporate Officer/Principal | 58 | 18-04-30 |
Lok Yee Chan
SEC | Corporate Secretary | 35 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Cheng Wei
BRD | Director/Board Member | 56 | 19-11-23 |
Ting Xu
CEO | Chief Executive Officer | 51 | 08-10-31 |
Yang Liu
COO | Chief Operating Officer | 52 | 18-09-30 |
Dong Wu
BRD | Director/Board Member | 54 | 19-11-23 |
Zijian Guo
BRD | Director/Board Member | 63 | 21-08-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 964,843,807 | 474,790,857 ( 49.21 %) | 0 | 49.21 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.23% | 629M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- 9966 Stock
- Company Alphamab Oncology